Abbott Laboratories (NYSE:ABT) received FDA authorization for its Libre Duo 10 Day system, described as the world's first dual glucose ketone sensing biowearable for diabetes management. The Libre Duo 10 Day device is designed to continuously track both glucose and ketone levels to help address risks linked to diabetic ketoacidosis. Abbott plans a U.S. launch of Libre Duo 10 Day following the FDA authorization, adding a new offering to its digital health and diagnostics portfolio. Investors...

Abbott Laboratories stock is trading just below $117 after U.S. regulators cleared a dual glucose-ke

Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, in a deal that comes a month after an Illinois federal judge tossed the suit.

Abbott Laboratories stock trades with a $670 million legal overhang after a formula settlement and a

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.

Abbott Laboratories stock is trading close to analysts’ consensus target, backed by strong Q2 diagno

The settlement resolves allegations that the products caused gastrointestinal disease among infants.